Primary Sclerosing Cholangitis (PSC) is a debilitating rare disease of the liver with no effective treatment. Reported in Nature Genetics researchers from the Wellcome Trust Sanger Institute, Mayo ...
SAN FRANCISCO--(BUSINESS WIRE)--Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective ...
Table 1 Association summary statistics across four newly associated PSC risk loci Figure 1: Odds ratios (and their 95% confidence intervals) for PSC, UC and CD across the six PSC-associated SNPs ...
Sayed “Obi” Aseem, M.D., Ph.D., is an assistant professor in the VCU School of Medicine’s Department of Internal Medicine and is part of the VCU Stravitz-Sanyal Institute for Liver Disease and ...
TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic ...
Tsukuba, Japan—Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct stricturing, which ultimately leads to cirrhosis and liver ...
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in ...
Primary Sclerosing Cholangitis (PSC) is a debilitating rare disease of the liver with no effective treatment. Researchers have now identified four regions of the genome associated with the disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback